3D systems delivering VEGF to promote angiogenesis for tissue engineering

被引:96
作者
des Rieux, Anne [1 ]
Ucakar, Bernard [1 ]
Mupendwa, Billy Paul Kaishusha [1 ]
Colau, Didier [2 ]
Feron, Olivier [3 ]
Carmeliet, Peter [4 ]
Preat, Veronique [1 ]
机构
[1] Catholic Univ Louvain, Louvain Drug Res Inst, Unite Pharm Galen, B-1200 Brussels, Belgium
[2] Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium
[3] Catholic Univ Louvain, Inst Rech Expt & Clin, B-1200 Brussels, Belgium
[4] Katholieke Univ Leuven VIB, Vesalius Res Ctr, B-3000 Louvain, Belgium
关键词
VEGF encapsulation; Hydrogel; Scaffolds; Angiogenesis; Tissue engineering;
D O I
10.1016/j.jconrel.2010.11.028
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
In most cases, vascularization is the first requirement to achieve tissue regeneration. The delivery from implants of angiogenic factors, like VEGF, has been widely investigated for establishing a vascular network within the developing tissue. In this report, we investigated if encapsulation of VEGF in nanoparticles could enhance angiogenesis in vivo as compared to free VEGF when incorporated into two different types of 3D matrices: Matrigel (TM) hydrogels and PLGA scaffolds. Negatively charged nanoparticles encapsulating VEGF were obtained with a high efficiency by complex formation with dextran sulfate and coacervation by chitosan. After 2 weeks, encapsulation reduced VEGF release from hydrogels from 30% to 1% and increased VEGF release from scaffolds from 20% to 30% in comparison with free VEGF. VEGF encapsulation consistently improved angiogenesis in vivo with both type of 3D matrices: up to 7.5- to 3.5-times more endothelial and red blood cells were observed, respectively, into hydrogels and scaffolds. Hence, encapsulation in nanoparticles enhanced VEGF efficiency by protection and controlled release from 3D implants. Encapsulation and incorporation of VEGF into 3D implants that, in addition to sustaining cell infiltration and organization, will stimulate blood vessel are a promising approach for tissue regeneration engineering. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:272 / 278
页数:7
相关论文
共 35 条
[31]
Sonveaux P, 2003, CANCER RES, V63, P1012
[32]
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS [J].
Storkebaum, E ;
Lambrechts, D ;
Dewerchin, M ;
Moreno-Murciano, MP ;
Appelmans, S ;
Oh, H ;
Van Damme, P ;
Rutten, B ;
Man, WY ;
De Mol, M ;
Wyns, S ;
Manka, D ;
Vermeulen, K ;
Van den Bosch, L ;
Mertens, N ;
Schmitz, C ;
Robberecht, W ;
Conway, EM ;
Collen, D ;
Moons, L ;
Carmeliet, P .
NATURE NEUROSCIENCE, 2005, 8 (01) :85-92
[33]
VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection [J].
Storkebaum, E ;
Lambrechts, D ;
Carmeliet, P .
BIOESSAYS, 2004, 26 (09) :943-954
[34]
Neurotrophin releasing single and multiple lumen nerve conduits [J].
Yang, Y ;
De Laporte, L ;
Rives, CB ;
Jang, JH ;
Lin, WC ;
Shull, KR ;
Shea, LD .
JOURNAL OF CONTROLLED RELEASE, 2005, 104 (03) :433-446
[35]
Biopolymeric delivery matrices for angiogenic growth factors [J].
Zisch, AH ;
Lutolf, MP ;
Hubbell, JA .
CARDIOVASCULAR PATHOLOGY, 2003, 12 (06) :295-310